Pharmacy Times January 17, 2025
Key Takeaways
- Xanomeline and trospium chloride (KarXT) target M1/M4 receptors, offering a new class of treatment for schizophrenia and Alzheimer’s-related psychosis.
- Fitusiran, an siRNA therapy, significantly reduces bleeding rates in hemophilia A or B, offering a new prophylactic option.
- Tarlatamab, a bispecific T cell engager, targets DLL3 in small cell lung cancer, potentially becoming a standard of care.
- Vepdegestrant, a PROTAC protein degrader, shows promise in ER+/HER2- breast cancer, with ongoing phase 3 trials.
- Zanzalintinib, a tyrosine kinase inhibitor, is being studied for non-clear-cell renal cell carcinoma and other cancers, with a potential 2026 launch.
These drugs are set to revolutionize their respective disease states in 2025.
Each year, dozens of new drugs are launched and enter the...
Today's Sponsors
Today's Sponsor